Showing results (11-20 of 1,214) with videos related to
Sort By:
Pageof 122
Clinical Neuropharmacology|February 1, 1996
Apomorphine tolerance in Parkinson's disease: lack of a dose effectS T Gancher, W R Woodward, J G NuttMovement Disorders : Official Journal of the Movement Disorder Society|January 1, 1995
Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of toleranceS T Gancher, J G Nutt, W R WoodwardAnnals of Neurology|June 1, 1987
3-O-methyldopa and the response to levodopa in Parkinson's diseaseJ G Nutt, W R Woodward, S T Gancher, et al.Annals of Neurology|August 1, 1989
Peripheral pharmacokinetics of apomorphine in humansS T Gancher, W R Woodward, B Boucher, et al.Clinical Neuropharmacology|October 1, 1992
Pharmacodynamics of the hypotensive effect of levodopa in parkinsonian patientsR P Irwin, J G Nutt, W R Woodward, et al.Archives of Neurology|November 1, 1992
Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenonJ G Nutt, W R Woodward, J H Carter, et al.Annals of Neurology|June 1, 1990
The short-duration response to apomorphine: implications for the mechanism of dopaminergic effects in parkinsonismS T Gancher, W R Woodward, P Gliessman, et al.Movement Disorders : Official Journal of the Movement Disorder Society|April 1, 1993
Does tolerance develop to levodopa? Comparison of 2- and 21-H levodopa infusionsJ G Nutt, J H Carter, W Woodward, et al.Clinical Neuropharmacology|February 1, 1992
Differences in the motor response to apomorphine between untreated and fluctuating patients with Parkinson's diseaseF Grandas, S T Gancher, M Rodriguez, et al.Clinical Neuropharmacology|October 1, 1994
Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patientsJ P Hammerstad, W R Woodward, J G Nutt, et al.Pageof 122